SlideShare a Scribd company logo
Adrenergic Agonists 
Chapter 30 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Adrenergic Agonists 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Definition 
– Called sympathomimetic drugs because they mimic 
the effects of the sympathetic nervous system (SNS) 
• Therapeutic and Adverse Effects 
– Related to their stimulation of adrenergic receptor 
sites 
• Uses 
– Varies from ophthalmic preparations for dilating 
pupils to systemic preparations for shock
Physiological Responses of Adrenergic 
Agonists 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Alpha- and Beta-Adrenergic Agonists and 
Their Indications 
• Epinephrine (Adrenalin, Sus-Phrine): Shock; glaucoma; 
prolongs effects of regional anesthetic 
• Norepinephrine (Levophed): Treat shock or during 
cardiac arrest to get sympathetic activity 
• Dopamine (Intropin): Shock 
• Dobutamine (Dobutrex): Congestive heart failure 
• Ephedrine (Pretz-D): Seasonal rhinitis; hypotensive 
episodes 
• Metaraminol (Aramine): Synthetic agent that is similar to 
norepinephrine 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Alpha- and Beta-Adrenergic Agonists 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Actions 
– The effects of these drug are mediated by the adrenergic 
receptors in target organs; heart rate increases, bronchi dilate, 
vasoconstriction occurs, intraocular pressure decreases, 
glycogenolysis occurs throughout the body 
• Indications 
– Treatment of hypotensive shock, bronchospasm, and some types 
of asthma 
• Pharmacokinetics 
– Rapidly absorbed after injection or passage through mucous 
membranes 
– Metabolized in the liver and excreted in the urine
Alpha- and Beta-Adrenergic Agonists 
(cont.) 
• Contraindications 
– Pheochromocytoma 
– Tachyarrhythmias or ventricular fibrillation 
– Hypovolemia 
– Halogenated hydrocarbon general anesthetics 
– Caution should be used with peripheral vascular 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
disease 
• Caution 
– PVD
Alpha- and Beta-Adrenergic Agonists 
(cont.) 
• Adverse Reactions 
– Arrhythmias, hypertension, palpitations, angina, 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
dyspnea 
– Nausea and vomiting 
– Headache and sweating 
• Drug-to-Drug Interaction 
– Tricyclic antidepressants and MAOI’s
Alpha-Specific Adrenergic Agonists 
(Alpha-Agonists) 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Definition 
– Drugs that bind primarily to alpha-receptors rather 
than to beta-receptors 
• Drugs In This Class 
– Phenylephrine (Neo-Synephrine, Allerest, AK-Dilate, 
and others) 
– Midodrine (ProAmantine) 
– Clonidine (Catapres)
Alpha-Specific Adrenergic Agonists 
(Alpha-Agonists) (cont.) 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Actions 
– Therapeutic effects come from the stimulation of alpha-receptors 
within the SNS 
• Indications 
– Hypertension, constriction of topical vessels in nose 
• Pharmacokinetics 
– Well absorbed and reach peak levels in a short period—20 
to 45 minutes 
– Widely distributed in the body 
– Metabolized in the liver and excreted in the urine
Alpha-Specific Adrenergic Agonists 
(Alpha-Agonists) (cont.) 
• Contraindications 
– Allergy to drug 
– Severe hypertension or tachycardia 
– Narrow-angle glaucoma 
– Pregnancy 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Caution 
– CVD or vasomotor spasm 
– Thyrotoxicosis or diabetes
Alpha-Specific Adrenergic Agonists 
(Alpha-Agonists) (cont.) 
• Adverse Reactions 
– Anxiety, restlessness, depression, fatigue, blurred 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
vision 
– ECG changes, arrhythmias, blood pressure changes 
– Nausea, vomiting 
– Decreased urinary output 
• Drug-to-Drug Interaction 
– MAOIs and TCAs 
– Digoxin and beta-blockers
Question 
Please identify the following statement as true or false. 
Another name for an adrenergic agonist drug is a 
sympathomimetic drug. 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Answer 
True 
Rationale: An adrenergic agonist is also called a 
sympathomimetic drug because it mimics the effects of 
the sympathetic nervous system (SNS). 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Beta-Specific Adrenergic Agonists and 
Their Indications 
• Isoproterenol (Isuprel) 
– Treatment of shock, cardiac standstill, and heart 
block in transplanted hearts; prevention of 
bronchospasm during anesthesia; inhaled to treat 
bronchospasm 
• Ritodrine (Yutopar) 
– Management of preterm labor 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Beta-Specific Adrenergic Agonists 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Actions 
– Effect is related to its stimulation of the beta-adrenergic 
receptors 
– Increase heart rate, conductivity, and contractility, 
bronchodilation, increase blood flow to skeletal muscles 
and splanchnic bed, and relaxation of uterus 
• Pharmacokinetics 
– Rapidly distributed after injection 
– Metabolized in the liver and excreted in the urine 
– T ½ less than 1 hour
Beta-Specific Adrenergic Agonists (cont.) 
• Contraindications 
– Allergy 
– Pulmonary hypertension 
– Eclampsia, uterine hemorrhage, and intrauterine death 
– Pregnancy and lactation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins 
• Caution 
– Diabetes, thyroid disease 
– Vasomotor problems 
– Heart disease and stroke
Beta-Specific Adrenergic Agonists (cont.) 
• Adverse Reactions 
– Restlessness, anxiety, and fear 
– Tachycardia, angina, MI, and palpitations 
– Difficulty breathing, cough, and bronchospasm 
– Nausea, vomiting, and anorexia 
• Drug-to-Drug Interaction 
– Increase with other sympathomimetic drugs 
– Decrease with beta adrenergic blockers 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Use of Adrenergic Agents Across 
the Lifespan 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Alpha- and Beta-Adrenergic 
Agonists 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Alpha-Agonists 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Prototype Beta-Specific Adrenergic 
Agonists 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for Alpha- and 
Beta-Adrenergic Agonists 
• Assessment: History and Physical Exam 
• Nursing Diagnosis 
• Implementation 
• Evaluation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for 
Alpha-Agonists 
• Assessment: History and Physical Exam 
• Nursing Diagnosis 
• Implementation 
• Evaluation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Nursing Considerations for Beta-Specific 
Adrenergic Agonists 
• Assessment: History and Physical Exam 
• Nursing Diagnosis 
• Implementation 
• Evaluation 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Question 
When providing care for a patient receiving alpha and beta 
adrenergic agonists, which of the following would be 
important to assess in order to prevent the systemic 
overload of catecholamines? 
A. Hypotension 
B. Pheochromocytoma 
C. Hypovolemia 
D. Allergic rhinitis 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
Answer 
B. Pheochromocytoma 
Rationale: Assess for contraindications or cautions 
including pheochromocytoma which could lead to fatal 
reactions due to systemic overload of catecholamines. 
Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins

More Related Content

What's hot

Ppt chapter 44
Ppt chapter 44Ppt chapter 44
Ppt chapter 44stanbridge
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48stanbridge
 
Ppt chapter 43
Ppt chapter 43Ppt chapter 43
Ppt chapter 43stanbridge
 
Ppt chapter 20-1
Ppt chapter 20-1Ppt chapter 20-1
Ppt chapter 20-1stanbridge
 
Ppt chapter 45
Ppt chapter 45Ppt chapter 45
Ppt chapter 45stanbridge
 
Ppt chapter 31
Ppt chapter 31Ppt chapter 31
Ppt chapter 31stanbridge
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16stanbridge
 
Ppt chapter 14
Ppt chapter 14Ppt chapter 14
Ppt chapter 14stanbridge
 
Ppt chapter 02
Ppt chapter 02Ppt chapter 02
Ppt chapter 02stanbridge
 
Ppt chapter 18
Ppt chapter 18Ppt chapter 18
Ppt chapter 18stanbridge
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48stanbridge
 
Ppt chapter 36-1
Ppt chapter 36-1Ppt chapter 36-1
Ppt chapter 36-1stanbridge
 
Ppt chapter 37-1
Ppt chapter 37-1Ppt chapter 37-1
Ppt chapter 37-1stanbridge
 
Anti migraine drugs
Anti migraine drugsAnti migraine drugs
Anti migraine drugs
Dr. Marya Ahsan
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36stanbridge
 
Drugs affecting Cardiovascular system
Drugs affecting Cardiovascular systemDrugs affecting Cardiovascular system
Drugs affecting Cardiovascular system
salman habeeb
 
Ppt chapter 26
Ppt chapter 26Ppt chapter 26
Ppt chapter 26stanbridge
 
Ppt chapter 51-1
Ppt chapter 51-1Ppt chapter 51-1
Ppt chapter 51-1stanbridge
 
Ppt chapter 40
Ppt chapter 40Ppt chapter 40
Ppt chapter 40stanbridge
 
Ppt chapter 13
Ppt chapter 13Ppt chapter 13
Ppt chapter 13stanbridge
 

What's hot (20)

Ppt chapter 44
Ppt chapter 44Ppt chapter 44
Ppt chapter 44
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48
 
Ppt chapter 43
Ppt chapter 43Ppt chapter 43
Ppt chapter 43
 
Ppt chapter 20-1
Ppt chapter 20-1Ppt chapter 20-1
Ppt chapter 20-1
 
Ppt chapter 45
Ppt chapter 45Ppt chapter 45
Ppt chapter 45
 
Ppt chapter 31
Ppt chapter 31Ppt chapter 31
Ppt chapter 31
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16
 
Ppt chapter 14
Ppt chapter 14Ppt chapter 14
Ppt chapter 14
 
Ppt chapter 02
Ppt chapter 02Ppt chapter 02
Ppt chapter 02
 
Ppt chapter 18
Ppt chapter 18Ppt chapter 18
Ppt chapter 18
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48
 
Ppt chapter 36-1
Ppt chapter 36-1Ppt chapter 36-1
Ppt chapter 36-1
 
Ppt chapter 37-1
Ppt chapter 37-1Ppt chapter 37-1
Ppt chapter 37-1
 
Anti migraine drugs
Anti migraine drugsAnti migraine drugs
Anti migraine drugs
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36
 
Drugs affecting Cardiovascular system
Drugs affecting Cardiovascular systemDrugs affecting Cardiovascular system
Drugs affecting Cardiovascular system
 
Ppt chapter 26
Ppt chapter 26Ppt chapter 26
Ppt chapter 26
 
Ppt chapter 51-1
Ppt chapter 51-1Ppt chapter 51-1
Ppt chapter 51-1
 
Ppt chapter 40
Ppt chapter 40Ppt chapter 40
Ppt chapter 40
 
Ppt chapter 13
Ppt chapter 13Ppt chapter 13
Ppt chapter 13
 

Viewers also liked

Adrenergic Drugs - drdhriti
Adrenergic Drugs - drdhritiAdrenergic Drugs - drdhriti
Adrenergic Drugs - drdhriti
http://neigrihms.gov.in/
 
Adrenergic agonists & antagonists
Adrenergic agonists & antagonistsAdrenergic agonists & antagonists
Adrenergic agonists & antagonists
Brian Piper
 
Autonomic nervous system (ANS-5)
Autonomic nervous system (ANS-5) Autonomic nervous system (ANS-5)
Autonomic nervous system (ANS-5)
Mohammed Naeem
 
ANS (SYMPATHETIC and PARASYMPATHETIC)
ANS (SYMPATHETIC and PARASYMPATHETIC)ANS (SYMPATHETIC and PARASYMPATHETIC)
ANS (SYMPATHETIC and PARASYMPATHETIC)
Shubham Roy
 
Physiology of ANS
Physiology of ANSPhysiology of ANS
Physiology of ANShavalprit
 
Adrenal agonist agents
Adrenal agonist agentsAdrenal agonist agents
Adrenal agonist agents
Self-employed researcher
 
Physiology ANS
Physiology ANSPhysiology ANS
Physiology ANS
Med Study
 
Ppt chapter 30
Ppt chapter 30Ppt chapter 30
Ppt chapter 30stanbridge
 
The Nervous System
The Nervous SystemThe Nervous System
The Nervous System
Sian Ferguson
 
Adrenergic agonists & antagonists in veterinary medicine
Adrenergic agonists & antagonists in veterinary medicine Adrenergic agonists & antagonists in veterinary medicine
Adrenergic agonists & antagonists in veterinary medicine
Dr. Sindhu K., Asst. Prof., Dept. of VPT, VCG.
 
Adrenergic agonists
Adrenergic agonistsAdrenergic agonists
Adrenergic agonistsLeul Mesfin
 
5. adrenergic drugs
5. adrenergic drugs5. adrenergic drugs
5. adrenergic drugs
IAU Dent
 
Dopamine And Pathways
Dopamine And PathwaysDopamine And Pathways
Dopamine And Pathways
Prashant Mishra
 
Ans pharmacology
Ans pharmacologyAns pharmacology
Ans pharmacology
Simba Syed
 
Antibiotic resistance
Antibiotic resistance Antibiotic resistance
Antibiotic resistance
Naser Tadvi
 
Antibiotics: classification and spectrum of action
Antibiotics: classification and spectrum of actionAntibiotics: classification and spectrum of action
Antibiotics: classification and spectrum of action
Bashar Mudallal
 

Viewers also liked (20)

Adrenergic Drugs - drdhriti
Adrenergic Drugs - drdhritiAdrenergic Drugs - drdhriti
Adrenergic Drugs - drdhriti
 
Adrenergic agonists & antagonists
Adrenergic agonists & antagonistsAdrenergic agonists & antagonists
Adrenergic agonists & antagonists
 
Autonomic nervous system (ANS-5)
Autonomic nervous system (ANS-5) Autonomic nervous system (ANS-5)
Autonomic nervous system (ANS-5)
 
ANS (SYMPATHETIC and PARASYMPATHETIC)
ANS (SYMPATHETIC and PARASYMPATHETIC)ANS (SYMPATHETIC and PARASYMPATHETIC)
ANS (SYMPATHETIC and PARASYMPATHETIC)
 
Abuse of antibiotics
Abuse of antibioticsAbuse of antibiotics
Abuse of antibiotics
 
Physiology of ANS
Physiology of ANSPhysiology of ANS
Physiology of ANS
 
Adrenal agonist agents
Adrenal agonist agentsAdrenal agonist agents
Adrenal agonist agents
 
Physiology ANS
Physiology ANSPhysiology ANS
Physiology ANS
 
Ppt chapter 30
Ppt chapter 30Ppt chapter 30
Ppt chapter 30
 
The Nervous System
The Nervous SystemThe Nervous System
The Nervous System
 
Adrenergic agonists & antagonists in veterinary medicine
Adrenergic agonists & antagonists in veterinary medicine Adrenergic agonists & antagonists in veterinary medicine
Adrenergic agonists & antagonists in veterinary medicine
 
Adrenergic drugs (VK)
Adrenergic drugs (VK)Adrenergic drugs (VK)
Adrenergic drugs (VK)
 
Adrenergic agonists
Adrenergic agonistsAdrenergic agonists
Adrenergic agonists
 
5. adrenergic drugs
5. adrenergic drugs5. adrenergic drugs
5. adrenergic drugs
 
Dopamine And Pathways
Dopamine And PathwaysDopamine And Pathways
Dopamine And Pathways
 
Ans pharmacology
Ans pharmacologyAns pharmacology
Ans pharmacology
 
L5: Adrenergic agonists; sympathomimetics
L5: Adrenergic agonists; sympathomimeticsL5: Adrenergic agonists; sympathomimetics
L5: Adrenergic agonists; sympathomimetics
 
L1: Drugs acting on the ANS
L1: Drugs acting on the ANSL1: Drugs acting on the ANS
L1: Drugs acting on the ANS
 
Antibiotic resistance
Antibiotic resistance Antibiotic resistance
Antibiotic resistance
 
Antibiotics: classification and spectrum of action
Antibiotics: classification and spectrum of actionAntibiotics: classification and spectrum of action
Antibiotics: classification and spectrum of action
 

Similar to Ppt chapter 30-1

Ppt chapter 59
Ppt chapter 59Ppt chapter 59
Ppt chapter 59stanbridge
 
Ppt chapter 16-1
Ppt chapter 16-1Ppt chapter 16-1
Ppt chapter 16-1stanbridge
 
Ppt chapter 59
Ppt chapter 59Ppt chapter 59
Ppt chapter 59stanbridge
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16stanbridge
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48stanbridge
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20stanbridge
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20stanbridge
 
Ppt chapter 40
Ppt chapter 40Ppt chapter 40
Ppt chapter 40stanbridge
 
Ppt chapter 52
Ppt chapter 52Ppt chapter 52
Ppt chapter 52stanbridge
 
Ppt chapter 35-1
Ppt chapter 35-1Ppt chapter 35-1
Ppt chapter 35-1stanbridge
 
Ppt chapter 35-1
Ppt chapter 35-1Ppt chapter 35-1
Ppt chapter 35-1stanbridge
 
Ppt chapter 35-1
Ppt chapter 35-1Ppt chapter 35-1
Ppt chapter 35-1stanbridge
 
Ppt chapter 52-1
Ppt chapter 52-1Ppt chapter 52-1
Ppt chapter 52-1stanbridge
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36stanbridge
 
Ppt chapter 37
Ppt chapter 37Ppt chapter 37
Ppt chapter 37stanbridge
 
Ppt chapter 32
Ppt chapter 32Ppt chapter 32
Ppt chapter 32stanbridge
 
Ppt chapter 41
Ppt chapter 41Ppt chapter 41
Ppt chapter 41stanbridge
 
Ppt chapter 24
Ppt chapter 24Ppt chapter 24
Ppt chapter 24stanbridge
 
Ppt chapter 24-1
Ppt chapter 24-1Ppt chapter 24-1
Ppt chapter 24-1stanbridge
 
Ppt chapter 57
Ppt chapter 57Ppt chapter 57
Ppt chapter 57stanbridge
 

Similar to Ppt chapter 30-1 (20)

Ppt chapter 59
Ppt chapter 59Ppt chapter 59
Ppt chapter 59
 
Ppt chapter 16-1
Ppt chapter 16-1Ppt chapter 16-1
Ppt chapter 16-1
 
Ppt chapter 59
Ppt chapter 59Ppt chapter 59
Ppt chapter 59
 
Ppt chapter 16
Ppt chapter 16Ppt chapter 16
Ppt chapter 16
 
Ppt chapter 48
Ppt chapter 48Ppt chapter 48
Ppt chapter 48
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20
 
Ppt chapter 20
Ppt chapter 20Ppt chapter 20
Ppt chapter 20
 
Ppt chapter 40
Ppt chapter 40Ppt chapter 40
Ppt chapter 40
 
Ppt chapter 52
Ppt chapter 52Ppt chapter 52
Ppt chapter 52
 
Ppt chapter 35-1
Ppt chapter 35-1Ppt chapter 35-1
Ppt chapter 35-1
 
Ppt chapter 35-1
Ppt chapter 35-1Ppt chapter 35-1
Ppt chapter 35-1
 
Ppt chapter 35-1
Ppt chapter 35-1Ppt chapter 35-1
Ppt chapter 35-1
 
Ppt chapter 52-1
Ppt chapter 52-1Ppt chapter 52-1
Ppt chapter 52-1
 
Ppt chapter 36
Ppt chapter 36Ppt chapter 36
Ppt chapter 36
 
Ppt chapter 37
Ppt chapter 37Ppt chapter 37
Ppt chapter 37
 
Ppt chapter 32
Ppt chapter 32Ppt chapter 32
Ppt chapter 32
 
Ppt chapter 41
Ppt chapter 41Ppt chapter 41
Ppt chapter 41
 
Ppt chapter 24
Ppt chapter 24Ppt chapter 24
Ppt chapter 24
 
Ppt chapter 24-1
Ppt chapter 24-1Ppt chapter 24-1
Ppt chapter 24-1
 
Ppt chapter 57
Ppt chapter 57Ppt chapter 57
Ppt chapter 57
 

More from stanbridge

Micro Lab 3 Lecture
Micro Lab 3 LectureMicro Lab 3 Lecture
Micro Lab 3 Lecture
stanbridge
 
Creating a poster v2
Creating a poster v2Creating a poster v2
Creating a poster v2
stanbridge
 
Creating a poster
Creating a posterCreating a poster
Creating a poster
stanbridge
 
Sample poster
Sample posterSample poster
Sample poster
stanbridge
 
OT 5018 Thesis Dissemination
OT 5018 Thesis DisseminationOT 5018 Thesis Dissemination
OT 5018 Thesis Dissemination
stanbridge
 
Ot5101 005 week 5
Ot5101 005 week 5Ot5101 005 week 5
Ot5101 005 week 5
stanbridge
 
Ot5101 005 week4
Ot5101 005 week4Ot5101 005 week4
Ot5101 005 week4
stanbridge
 
Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors
stanbridge
 
Ch 5 developmental stages of the learner
Ch 5   developmental stages of the learnerCh 5   developmental stages of the learner
Ch 5 developmental stages of the learner
stanbridge
 
OT 5101 week2 theory policy
OT 5101 week2 theory policyOT 5101 week2 theory policy
OT 5101 week2 theory policy
stanbridge
 
OT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentOT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessment
stanbridge
 
Ot5101 week1
Ot5101 week1Ot5101 week1
Ot5101 week1
stanbridge
 
NUR 304 Chapter005
NUR 304 Chapter005NUR 304 Chapter005
NUR 304 Chapter005
stanbridge
 
NUR 3043 Chapter007
NUR 3043 Chapter007NUR 3043 Chapter007
NUR 3043 Chapter007
stanbridge
 
NUR 3043 Chapter006
NUR 3043 Chapter006NUR 3043 Chapter006
NUR 3043 Chapter006
stanbridge
 
NUR 3043 Chapter004
NUR 3043 Chapter004NUR 3043 Chapter004
NUR 3043 Chapter004
stanbridge
 
3043 Chapter009
3043 Chapter0093043 Chapter009
3043 Chapter009
stanbridge
 
3043 Chapter008
 3043 Chapter008 3043 Chapter008
3043 Chapter008
stanbridge
 
Melnyk ppt chapter_21
Melnyk ppt chapter_21Melnyk ppt chapter_21
Melnyk ppt chapter_21
stanbridge
 
Melnyk ppt chapter_22
Melnyk ppt chapter_22Melnyk ppt chapter_22
Melnyk ppt chapter_22
stanbridge
 

More from stanbridge (20)

Micro Lab 3 Lecture
Micro Lab 3 LectureMicro Lab 3 Lecture
Micro Lab 3 Lecture
 
Creating a poster v2
Creating a poster v2Creating a poster v2
Creating a poster v2
 
Creating a poster
Creating a posterCreating a poster
Creating a poster
 
Sample poster
Sample posterSample poster
Sample poster
 
OT 5018 Thesis Dissemination
OT 5018 Thesis DisseminationOT 5018 Thesis Dissemination
OT 5018 Thesis Dissemination
 
Ot5101 005 week 5
Ot5101 005 week 5Ot5101 005 week 5
Ot5101 005 week 5
 
Ot5101 005 week4
Ot5101 005 week4Ot5101 005 week4
Ot5101 005 week4
 
Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors Compliance, motivation, and health behaviors
Compliance, motivation, and health behaviors
 
Ch 5 developmental stages of the learner
Ch 5   developmental stages of the learnerCh 5   developmental stages of the learner
Ch 5 developmental stages of the learner
 
OT 5101 week2 theory policy
OT 5101 week2 theory policyOT 5101 week2 theory policy
OT 5101 week2 theory policy
 
OT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessmentOT 5101 week3 planning needs assessment
OT 5101 week3 planning needs assessment
 
Ot5101 week1
Ot5101 week1Ot5101 week1
Ot5101 week1
 
NUR 304 Chapter005
NUR 304 Chapter005NUR 304 Chapter005
NUR 304 Chapter005
 
NUR 3043 Chapter007
NUR 3043 Chapter007NUR 3043 Chapter007
NUR 3043 Chapter007
 
NUR 3043 Chapter006
NUR 3043 Chapter006NUR 3043 Chapter006
NUR 3043 Chapter006
 
NUR 3043 Chapter004
NUR 3043 Chapter004NUR 3043 Chapter004
NUR 3043 Chapter004
 
3043 Chapter009
3043 Chapter0093043 Chapter009
3043 Chapter009
 
3043 Chapter008
 3043 Chapter008 3043 Chapter008
3043 Chapter008
 
Melnyk ppt chapter_21
Melnyk ppt chapter_21Melnyk ppt chapter_21
Melnyk ppt chapter_21
 
Melnyk ppt chapter_22
Melnyk ppt chapter_22Melnyk ppt chapter_22
Melnyk ppt chapter_22
 

Ppt chapter 30-1

  • 1. Adrenergic Agonists Chapter 30 Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 2. Adrenergic Agonists Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Definition – Called sympathomimetic drugs because they mimic the effects of the sympathetic nervous system (SNS) • Therapeutic and Adverse Effects – Related to their stimulation of adrenergic receptor sites • Uses – Varies from ophthalmic preparations for dilating pupils to systemic preparations for shock
  • 3. Physiological Responses of Adrenergic Agonists Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 4. Alpha- and Beta-Adrenergic Agonists and Their Indications • Epinephrine (Adrenalin, Sus-Phrine): Shock; glaucoma; prolongs effects of regional anesthetic • Norepinephrine (Levophed): Treat shock or during cardiac arrest to get sympathetic activity • Dopamine (Intropin): Shock • Dobutamine (Dobutrex): Congestive heart failure • Ephedrine (Pretz-D): Seasonal rhinitis; hypotensive episodes • Metaraminol (Aramine): Synthetic agent that is similar to norepinephrine Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 5. Alpha- and Beta-Adrenergic Agonists Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Actions – The effects of these drug are mediated by the adrenergic receptors in target organs; heart rate increases, bronchi dilate, vasoconstriction occurs, intraocular pressure decreases, glycogenolysis occurs throughout the body • Indications – Treatment of hypotensive shock, bronchospasm, and some types of asthma • Pharmacokinetics – Rapidly absorbed after injection or passage through mucous membranes – Metabolized in the liver and excreted in the urine
  • 6. Alpha- and Beta-Adrenergic Agonists (cont.) • Contraindications – Pheochromocytoma – Tachyarrhythmias or ventricular fibrillation – Hypovolemia – Halogenated hydrocarbon general anesthetics – Caution should be used with peripheral vascular Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins disease • Caution – PVD
  • 7. Alpha- and Beta-Adrenergic Agonists (cont.) • Adverse Reactions – Arrhythmias, hypertension, palpitations, angina, Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins dyspnea – Nausea and vomiting – Headache and sweating • Drug-to-Drug Interaction – Tricyclic antidepressants and MAOI’s
  • 8. Alpha-Specific Adrenergic Agonists (Alpha-Agonists) Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Definition – Drugs that bind primarily to alpha-receptors rather than to beta-receptors • Drugs In This Class – Phenylephrine (Neo-Synephrine, Allerest, AK-Dilate, and others) – Midodrine (ProAmantine) – Clonidine (Catapres)
  • 9. Alpha-Specific Adrenergic Agonists (Alpha-Agonists) (cont.) Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Actions – Therapeutic effects come from the stimulation of alpha-receptors within the SNS • Indications – Hypertension, constriction of topical vessels in nose • Pharmacokinetics – Well absorbed and reach peak levels in a short period—20 to 45 minutes – Widely distributed in the body – Metabolized in the liver and excreted in the urine
  • 10. Alpha-Specific Adrenergic Agonists (Alpha-Agonists) (cont.) • Contraindications – Allergy to drug – Severe hypertension or tachycardia – Narrow-angle glaucoma – Pregnancy Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Caution – CVD or vasomotor spasm – Thyrotoxicosis or diabetes
  • 11. Alpha-Specific Adrenergic Agonists (Alpha-Agonists) (cont.) • Adverse Reactions – Anxiety, restlessness, depression, fatigue, blurred Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins vision – ECG changes, arrhythmias, blood pressure changes – Nausea, vomiting – Decreased urinary output • Drug-to-Drug Interaction – MAOIs and TCAs – Digoxin and beta-blockers
  • 12. Question Please identify the following statement as true or false. Another name for an adrenergic agonist drug is a sympathomimetic drug. Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 13. Answer True Rationale: An adrenergic agonist is also called a sympathomimetic drug because it mimics the effects of the sympathetic nervous system (SNS). Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 14. Beta-Specific Adrenergic Agonists and Their Indications • Isoproterenol (Isuprel) – Treatment of shock, cardiac standstill, and heart block in transplanted hearts; prevention of bronchospasm during anesthesia; inhaled to treat bronchospasm • Ritodrine (Yutopar) – Management of preterm labor Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 15. Beta-Specific Adrenergic Agonists Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Actions – Effect is related to its stimulation of the beta-adrenergic receptors – Increase heart rate, conductivity, and contractility, bronchodilation, increase blood flow to skeletal muscles and splanchnic bed, and relaxation of uterus • Pharmacokinetics – Rapidly distributed after injection – Metabolized in the liver and excreted in the urine – T ½ less than 1 hour
  • 16. Beta-Specific Adrenergic Agonists (cont.) • Contraindications – Allergy – Pulmonary hypertension – Eclampsia, uterine hemorrhage, and intrauterine death – Pregnancy and lactation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins • Caution – Diabetes, thyroid disease – Vasomotor problems – Heart disease and stroke
  • 17. Beta-Specific Adrenergic Agonists (cont.) • Adverse Reactions – Restlessness, anxiety, and fear – Tachycardia, angina, MI, and palpitations – Difficulty breathing, cough, and bronchospasm – Nausea, vomiting, and anorexia • Drug-to-Drug Interaction – Increase with other sympathomimetic drugs – Decrease with beta adrenergic blockers Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 18. Use of Adrenergic Agents Across the Lifespan Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 19. Prototype Alpha- and Beta-Adrenergic Agonists Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 20. Prototype Alpha-Agonists Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 21. Prototype Beta-Specific Adrenergic Agonists Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 22. Nursing Considerations for Alpha- and Beta-Adrenergic Agonists • Assessment: History and Physical Exam • Nursing Diagnosis • Implementation • Evaluation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 23. Nursing Considerations for Alpha-Agonists • Assessment: History and Physical Exam • Nursing Diagnosis • Implementation • Evaluation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 24. Nursing Considerations for Beta-Specific Adrenergic Agonists • Assessment: History and Physical Exam • Nursing Diagnosis • Implementation • Evaluation Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 25. Question When providing care for a patient receiving alpha and beta adrenergic agonists, which of the following would be important to assess in order to prevent the systemic overload of catecholamines? A. Hypotension B. Pheochromocytoma C. Hypovolemia D. Allergic rhinitis Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins
  • 26. Answer B. Pheochromocytoma Rationale: Assess for contraindications or cautions including pheochromocytoma which could lead to fatal reactions due to systemic overload of catecholamines. Copyright © 2013 Wolters Kluwer Health | Lippincott Williams & Wilkins